Article
Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy.
Thoracic cancer - 1 Jan 2020
Lv Panpan, Yang Shaoxing, Liu Wenjing, Qin Haifeng, Tang Xiuhua, Wu Fangfang, Liu Zeyuan, Gao Hongjun, Liu Xiaoqing
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). However, even patients with EGFR-sensitive mutations in NSCLC have limited efficacy with EGFR-TKI. Studies have shown that long noncoding RNA (lncRNA) is related to diagnosis and prognosis with NSCLC. This study aimed to explore the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.